NO942913L - Fremgangsmåte for fremstilling av inflammatoriske dermatoser - Google Patents

Fremgangsmåte for fremstilling av inflammatoriske dermatoser

Info

Publication number
NO942913L
NO942913L NO942913A NO942913A NO942913L NO 942913 L NO942913 L NO 942913L NO 942913 A NO942913 A NO 942913A NO 942913 A NO942913 A NO 942913A NO 942913 L NO942913 L NO 942913L
Authority
NO
Norway
Prior art keywords
corticosteroid
preparation
retinoid
treatment
healing
Prior art date
Application number
NO942913A
Other languages
English (en)
Norwegian (no)
Other versions
NO942913D0 (ko
Inventor
Albert M Kligman
Original Assignee
Albert M Kligman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert M Kligman filed Critical Albert M Kligman
Publication of NO942913D0 publication Critical patent/NO942913D0/no
Publication of NO942913L publication Critical patent/NO942913L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO942913A 1992-02-07 1994-08-05 Fremgangsmåte for fremstilling av inflammatoriske dermatoser NO942913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83282892A 1992-02-07 1992-02-07
PCT/US1993/001043 WO1993015740A1 (en) 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses

Publications (2)

Publication Number Publication Date
NO942913D0 NO942913D0 (ko) 1994-08-05
NO942913L true NO942913L (no) 1994-10-05

Family

ID=25262717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942913A NO942913L (no) 1992-02-07 1994-08-05 Fremgangsmåte for fremstilling av inflammatoriske dermatoser

Country Status (12)

Country Link
US (1) US5998395A (ko)
EP (1) EP0625045A4 (ko)
JP (1) JP2927961B2 (ko)
KR (1) KR100282575B1 (ko)
AU (1) AU667519B2 (ko)
CA (1) CA2129114A1 (ko)
CZ (1) CZ188394A3 (ko)
FI (1) FI943625A (ko)
NO (1) NO942913L (ko)
NZ (1) NZ249379A (ko)
WO (1) WO1993015740A1 (ko)
ZA (1) ZA93811B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
JPH08501552A (ja) * 1992-09-11 1996-02-20 ブラウン，サンドラ 脱毛治療方法および組成物
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
ATE223714T1 (de) * 1995-05-05 2002-09-15 Mark S Braiman Behandlung der psoriasis mit 11-cis-retinsäure
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US6355669B1 (en) * 1997-10-22 2002-03-12 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
ATE402692T1 (de) * 2000-05-09 2008-08-15 Kaneka Corp Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
AU2002242302A1 (en) * 2001-03-02 2002-09-19 Spectra Systems Corporation Combinatorial chemistry and compound identification system
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
US20030199488A1 (en) * 2002-04-23 2003-10-23 Trotta Gina M. Treatment of hyperproliferative disorders/inflammatory dermatoses
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
CA2528776A1 (en) * 2002-10-24 2004-05-06 G & R Pharmaceuticals, Llc Antifungal formulations
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
CA2546347A1 (en) * 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
CN1942178A (zh) * 2004-02-19 2007-04-04 奥克塞尔公司 用于治疗皮肤疾病的局部制剂
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
BRPI0516202A (pt) 2004-09-28 2008-08-26 Chemaphor Inc produto para alimentação de um animal, uso, kit e método de preparação deste produto
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
JP2011500733A (ja) 2007-10-26 2011-01-06 ケマファー インコーポレーテッド 免疫応答を増強するための組成物および方法
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
EP2424512B1 (en) 2009-04-30 2020-06-03 Avivagen Inc. Methods and compositions for improving the health of animals
WO2011050102A1 (en) 2009-10-20 2011-04-28 Discovery Partners, LLC Dermatologic and cosmetic compositions
ES2378028B1 (es) 2012-02-22 2013-02-18 Ignacio Umbert Millet Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes
JP7416687B2 (ja) * 2017-09-28 2024-01-17 ジョンソン アンド ジョンソン コンシューマー インコーポレイテッド 化粧品組成物及び皮膚の処置方法
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
ZA77678B (en) * 1977-02-07 1978-09-27 S Fourie Pharmaceutical composition and use thereof
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy

Also Published As

Publication number Publication date
KR950700069A (ko) 1995-01-16
NO942913D0 (ko) 1994-08-05
FI943625A0 (fi) 1994-08-04
US5998395A (en) 1999-12-07
FI943625A (fi) 1994-08-04
KR100282575B1 (ko) 2001-02-15
AU667519B2 (en) 1996-03-28
EP0625045A4 (en) 1995-01-18
JPH07505617A (ja) 1995-06-22
CA2129114A1 (en) 1993-08-19
EP0625045A1 (en) 1994-11-23
ZA93811B (en) 1993-09-10
WO1993015740A1 (en) 1993-08-19
AU3585493A (en) 1993-09-03
CZ188394A3 (en) 1996-02-14
NZ249379A (en) 1998-07-28
JP2927961B2 (ja) 1999-07-28

Similar Documents

Publication Publication Date Title
NO942913L (no) Fremgangsmåte for fremstilling av inflammatoriske dermatoser
NZ261990A (en) Treating bronchial asthma with topical anaesthetics
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
ES2092460T3 (es) Composicion dadora de oxido nitrico para el tratamiento de trastornos anales.
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
ATE421877T1 (de) Verwendung von totarol zur behandlung von pruritus
DE59407336D1 (de) Verwendung von Cineol oder Menthol zur Behandlung von Asthma
DE69519582D1 (de) Kontrolle des haarwuchses
ATE151977T1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
Potter et al. Erythrodermic psoriasis after discontinuation of ixekizumab
NO961589L (no) Farmasöytiske blandinger
NO982935L (no) Hyaluronsyre reseptor bindemiddel og anvendelse derav
Yan et al. Effect of acupuncture at different meridian acupoints on changes of related factors for rabbit gastric mucosal injury
RU2230549C2 (ru) Способ лечения аллергических дерматозов
Rosted Treatment of skin diseases with acupuncture a review
ATE240110T1 (de) Verwendung von natriumchlorid zur behandlung der akne und/oder der rosacea
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
RU2696532C2 (ru) Способ моделирования лимфовенозной недостаточности в тазовых органах
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
Angelo-Khattar et al. Vascular effects of glucocorticosteroids, with special reference to budesonide
Pacurari et al. Inhibiting NF-κB Attenuates H2O2-Induced MMP-9 and MMP-12 Expression
RU2067010C1 (ru) Способ лечения трофических язв
Amin et al. Treatment of vascular leg ulcers with leukocyte-and platelet-rich fibrin (L-PRF): A systematic review
Eaton et al. What is the best treatment for plant-induced contact dermatitis?